WCN26-5830 A TRANSLATIONAL FRAMEWORK TO PREDICT CLINICAL RESPONSES TO APRIL BLOCKADE FOR DEVELOPMENT OF JADE101, AN ANTI-APRIL MONOCLONAL ANTIBODY IN IgAN

Read full text Summarise with VIRAT
Authors: Li Li, Todd A. DeVries, Vincent W. Tong, Sandy Lewis, Erin L. Filbert, Andrew King, Brandon T. Gufford
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN) is an autoimmune kidney disease characterized by mesangial deposition of immune complexes containing IgA and Gd-IgA1. Blocking A proliferation-inducing ligand (APRIL) is potentially disease modifying in IgAN by reducing IgA, Gd-IgA1 and proteinuria, ultimately stabilizing kidney function. JADE101 is a novel APRIL neutralizing monoclonal antibody (mAb) designed with high affinity and extended half-life. Biomarker responses to APRIL inhibition were leveraged to assess preclinical to clinical translation and the consistency of pharmacokinetic (PK) and pharmacodynamic (PD) responses in healthy volunteers (HV) and IgAN patients to support development of APRIL targeted therapies in IgAN.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Monoclonal and Polyclonal Antibodies Research Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104484–104484
Publication date
25 March 2026
Language
EN